Physician profile
Dane Todd Johnson
NPI 1497252647
$3,585.62
in general payments reported to CMS, 2019-2025
24 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $232 · 2022: $32.55 · 2023: $14.39 · 2024: $925 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.47 |
| Education | $186.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $769.88 | 2021-2025 | |
| Janssen Biotech, INC. | $486.59 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $363.43 | 2024-2025 | Dupixent |
| Pfizer INC. | $233.83 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $224.67 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $204.63 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.92 | 2024-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $155.24 | 2022-2025 | Livdelzi |
| Ardelyx, INC. | $148.50 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $147.32 | 2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $113.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.99 | 2024-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $71.43 | 2024 | |
| Phathom Pharmaceuticals, INC. | $70.02 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $68.60 | 2025 | Rezdiffra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $64.06 | 2024-2025 | Zenpep |
| Mallinckrodt Hospital Products INC. | $30.21 | 2025 | Terlivaz |
| Olympus America INC. | $29.34 | 2022-2023 | Long Clip |
| Qol Medical, LLC | $28.03 | 2024 | Sucraid |
| Vivus LLC | $23.64 | 2024 | Qsymia |
| Daiichi Sankyo INC. | $22.09 | 2024 | Injectafer |
| Organon LLC | $20.60 | 2025 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $14.87 | 2025 | |
| Ironwood Pharmaceuticals, INC | $14.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dane Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.